MSB 7.69% $1.19 mesoblast limited

Regenerative Medicine and Cell Therapies Virtual Event, page-29

  1. 5,481 Posts.
    lightbulb Created with Sketch. 8927
    we knew about the CLBP phase 3 trial in Europe, but there was always ambiguity on whether or not the advanced CHF trial needed a second phase 3 trial. I recalled hearing that there was one a while back, but couldn’t find the source.

    I think this confirms that there will be a second phase 3 trial for advanced CHF.

    The second phase 3 trials are likely to be modified with the data from both trials in totality being used as pivotal data. The CLBP phase 3 in Europe is going to be a 12 month primary endpoint, rather than the 24 month primary endpoint for the phase 3 trial that is going to read our next quarter.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.